Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company's iPSCelz® program, which is validated by Greenstone Biosciences Inc. ("Greenstone"). The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells. iPSCelz®, which is protected by trade secrets and published U.S. patents, utilizes the companies xeno-free human perinatal cell li ...